Figure 7: Q2-3 administration can confer a complementary anti-metastatic effect on human cancer cells (MDA-MB-231), when used in combination with docetaxel.

(a) Representative bioluminescent images of MDA-MB-231 tumour-bearing nude mice (n=8 per group) after in vivo treatment with PBS (0.1% DMSO in saline), Q2-3 (100 μg kg⁻¹), docetaxel (5 mg kg⁻¹) or co-treatment with docetaxel and Q2-3 for 3 weeks, after resection of the orthotopic primary tumours. In PBS-treated (control) and docetaxel-treated groups, one mice was died before 3 weeks post tumour resection. (b) Quantification of tumour metastasis by measuring luciferase activity in photons s⁻¹ cm⁻² sr⁻¹ in mice revealed along the indicated time course. (c) Survival of test mice after different treatments. P<0.05, were obtained between the docetaxel- and co-treated mice (Kaplan–Meier results were analysed by log-rank test). Similar results were obtained from two or three independent experiments.